Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PIRS
  • CUSIP: N/A
  • Web: www.pieris.com
Capitalization:
  • Market Cap: $173.11 million
  • Outstanding Shares: 43,063,000
Average Prices:
  • 50 Day Moving Avg: $2.96
  • 200 Day Moving Avg: $2.19
  • 52 Week Range: $1.30 - $4.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.28
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.93 million
  • Price / Sales: 29.19
  • Book Value: $0.42 per share
  • Price / Book: 9.57
Profitability:
  • EBIDTA: ($26,030,000.00)
  • Net Margins: -364.96%
  • Return on Equity: -60.26%
  • Return on Assets: -47.47%
Debt:
  • Current Ratio: 4.13%
  • Quick Ratio: 4.13%
Misc:
  • Average Volume: 1.04 million shs.
  • Beta: 1.91
  • Short Ratio: 3.39
 

Frequently Asked Questions for Pieris Pharmaceuticals (NASDAQ:PIRS)

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.16 by $0.35. The company earned $1.34 million during the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 364.96% and a negative return on equity of 60.26%. View Pieris Pharmaceuticals' Earnings History.

Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2017?

2 brokers have issued 1-year price objectives for Pieris Pharmaceuticals' shares. Their predictions range from $6.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $7.50 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

Who owns Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tekla Capital Management LLC (9.15%), Omega Fund Management LLC (3.94%), Sphera Funds Management LTD. (2.32%), Renaissance Technologies LLC (0.59%), Morgan Stanley (0.45%) and Creative Planning (0.14%). Company insiders that own Pieris Pharmaceuticals stock include Darlene M Deptula-Hicks, Louis Matis and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Who sold Pieris Pharmaceuticals stock? Who is selling Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

Who bought Pieris Pharmaceuticals stock? Who is buying Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sphera Funds Management LTD., Creative Planning and Morgan Stanley. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Darlene M Deptula-Hicks, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy Pieris Pharmaceuticals stock?

Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pieris Pharmaceuticals stock cost?

One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $4.02.

Analyst Ratings

Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (86.57% upside)

Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Oppenheimer Holdings Inc.Set Price TargetBuy$9.00LowView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Earnings History by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017$0.16($0.19)$32.30 million$1.34 millionViewN/AView Earnings Details
8/10/2016Q216($0.15)($0.14)$1.08 million$1.07 millionViewN/AView Earnings Details
5/11/2016Q116($0.12)($0.10)$6.40 million$1.25 millionViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/11/2015Q315($0.11)($0.10)$0.23 million$0.42 millionViewN/AView Earnings Details
8/12/2015Q215($0.14)($0.12)$0.25 million$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
2017 EPS Consensus Estimate: $0.05
2018 EPS Consensus Estimate: ($0.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.52$0.52$0.52
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.02)($0.02)($0.02)
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Insider Ownership Percentage: 2.43%
Institutional Ownership Percentage: 47.58%
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.00View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.00View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pieris Pharmaceuticals (NASDAQ:PIRS)
Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
Source:
DateHeadline
finance.yahoo.com logoPieris Pharmaceuticals Appoints James Geraghty to its Board of Directors
finance.yahoo.com - May 22 at 6:24 PM
americanbankingnews.com logoPieris Pharmaceuticals Inc (PIRS) Expected to Earn Q1 2018 Earnings of ($0.22) Per Share
www.americanbankingnews.com - May 15 at 9:06 AM
americanbankingnews.com logoPieris Pharmaceuticals Inc (PIRS) Issues Earnings Results
www.americanbankingnews.com - May 11 at 7:18 PM
finance.yahoo.com logoPieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update
finance.yahoo.com - May 10 at 7:28 PM
finance.yahoo.com logoPieris Pharmaceuticals reports 1Q loss
finance.yahoo.com - May 10 at 7:28 PM
americanbankingnews.com logoPieris Pharmaceuticals (PIRS) Earns Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - May 8 at 11:45 PM
americanbankingnews.com logoPieris Pharmaceuticals Inc (PIRS) Rating Increased to C- at TheStreet
www.americanbankingnews.com - May 6 at 11:52 PM
finanznachrichten.de logoGainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI...
www.finanznachrichten.de - May 5 at 12:26 AM
americanbankingnews.com logoPieris Pharmaceuticals (PIRS) Earning Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 11:17 AM
americanbankingnews.com logoZacks: Pieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 4 at 8:12 AM
finance.yahoo.com logoPieris Pharmaceuticals to Host First Quarter 2017 Investor Call and Corporate Update on May 11, 2017
finance.yahoo.com - May 1 at 11:34 AM
americanbankingnews.com logoPieris Pharmaceuticals (PIRS) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 28 at 11:38 PM
americanbankingnews.com logoPieris Pharmaceuticals Inc (PIRS) PT Set at $9.00 by Oppenheimer Holdings Inc.
www.americanbankingnews.com - April 18 at 7:48 AM
americanbankingnews.com logoPieris Pharmaceuticals Inc Expected to Post Q1 2017 Earnings of $0.52 Per Share (PIRS)
www.americanbankingnews.com - April 14 at 8:12 AM
americanbankingnews.com logoOppenheimer Holdings Inc. Analysts Give Pieris Pharmaceuticals Inc (PIRS) a $9.00 Price Target
www.americanbankingnews.com - April 13 at 6:14 PM
americanbankingnews.com logoPieris Pharmaceuticals (PIRS) Given Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 13 at 12:48 PM
finance.yahoo.com logoPieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
finance.yahoo.com - April 7 at 11:55 AM
americanbankingnews.com logo Pieris Pharmaceuticals Inc (PIRS) Given $8.50 Average Target Price by Analysts
www.americanbankingnews.com - April 4 at 12:46 AM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 7:31 PM
seekingalpha.com logoPieris Pharmaceuticals Inc. (PIRS) CEO Stephen Yoder on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 23 at 7:42 PM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 23 at 8:42 AM
seekingalpha.com logoPieris Pharmaceuticals (PIRS) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 7:13 PM
finance.yahoo.com logoPieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017
finance.yahoo.com - March 15 at 9:24 AM
finance.yahoo.com logoPieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT
finance.yahoo.com - March 14 at 10:15 AM
finance.yahoo.com logoPieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST
finance.yahoo.com - March 7 at 9:44 AM
finance.yahoo.com logoPieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)
finance.yahoo.com - March 6 at 6:37 PM
finance.yahoo.com logoPieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST
finance.yahoo.com - March 1 at 9:32 AM
streetinsider.com logoPieris Pharma (PIRS) Grants Exclusive Option for PRS-080 in Japan to ASKA Pharmaceutical
www.streetinsider.com - February 27 at 9:49 AM
us.rd.yahoo.com logoPieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical
us.rd.yahoo.com - February 27 at 9:49 AM
marketwatch.com logoPieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA
www.marketwatch.com - February 27 at 9:49 AM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors
us.rd.yahoo.com - February 8 at 8:12 PM
finance.yahoo.com logoPieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST
finance.yahoo.com - February 8 at 8:12 PM
streetinsider.com logoPieris Pharma (PIRS) CFO to Resign - StreetInsider.com
www.streetinsider.com - February 8 at 2:04 AM
streetinsider.com logoPieris Pharma (PIRS) CFO to Resign
www.streetinsider.com - February 7 at 9:02 PM
us.rd.yahoo.com logoPieris Announces Management Transition
us.rd.yahoo.com - February 7 at 9:02 PM
biz.yahoo.com logoPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - January 9 at 7:55 PM
us.rd.yahoo.com logo7:48 am Pieris Pharmaceuticals provides 2017 milestones in slide presentation
us.rd.yahoo.com - January 9 at 7:55 PM

Social

Chart

Pieris Pharmaceuticals (PIRS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff